What is PROCEPT BioRobotics?
PROCEPT BioRobotics, incorporated in 2007 and headquartered in San Jose, California, is dedicated to advancing minimally invasive urologic surgery. The company designs, manufactures, and markets image-guided robotic systems primarily for the treatment of benign prostatic hyperplasia (BPH). Its innovative platform integrates real-time multidimensional imaging, personalized treatment planning, automated robotics, and heat-free waterjet ablation. This technology aims to provide consistent and durable surgical outcomes, irrespective of prostate characteristics or surgeon expertise. PROCEPT BioRobotics is publicly traded on the NASDAQ under the ticker symbol PRCT.
How much funding has PROCEPT BioRobotics raised?
PROCEPT BioRobotics has raised a total of $601.3M across 10 funding rounds:
Series C
$6M
Debt
$7.7M
Series A
$7.7M
Series D
$42M
Series B
$42M
Series E
$118M
Series F
$77M
Series G
$85M
Share Placement
$163.9M
Debt
$52M
Series C (2013): $6M, investors not publicly disclosed
Debt (2014): $7.7M, investors not publicly disclosed
Series A (2014): $7.7M, investors not publicly disclosed
Series D (2015): $42M featuring Novo A/S
Series B (2015): $42M backed by Novo Holdings
Series E (2018): $118M with participation from CPMG, Perceptive Advisors, and Viking Global Investors
Series F (2020): $77M, investors not publicly disclosed
Series G (2021): $85M supported by Perceptive Advisors, Fidelity Investments, Viking Global Investors, CPMG, T. Rowe Price, and Duquesne Family Office
Share Placement (2021): $163.9M, investors not publicly disclosed
Debt (2022): $52M backed by CIBC Innovation Banking
Key Investors in PROCEPT BioRobotics
Novo A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on investments in life sciences and healthcare.
Perceptive Advisors
Perceptive Advisors is a New York-based investment firm specializing in funding innovative healthcare and life sciences technologies.
Viking Global Investors
Viking Global Investors is a global investment firm employing research-intensive, long-term focused strategies across various industries and geographies.
What's next for PROCEPT BioRobotics?
With substantial enterprise-level backing and a recent strategic investment, PROCEPT BioRobotics is poised for significant advancements in the surgical robotics sector. The company's focus on urology, particularly BPH treatment, positions it to capitalize on a large and growing market. Future developments are likely to involve expanding the application of its robotic platform, further refining its therapeutic capabilities, and increasing market penetration. The ongoing capital infusion will support research and development, manufacturing scale-up, and broader commercialization efforts, solidifying its trajectory as a key player in surgical innovation.
See full PROCEPT BioRobotics company page
